This suggests that Tp53 loss drives progression from fibroadenoma to carcinoma, while PIK3CA activation restricts Tp53-mutated cells from transdifferentiation, unlike Tp53Indel-only tumors. This evidence concerns the gene TP53 and carcinoma.